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Antifungal drugs belong to few chemical groups and such low diversity limits the
therapeutic choices. The urgent need of innovative options has pushed researchers
to search new bioactive molecules. Literature regarding the last 15 years reveals
that different research groups have used different approaches to achieve such goal.
However, the discovery of molecules with different mechanisms of action still demands
considerable time and efforts. This review was conceived to present how Pharmaceutical
Biotechnology might contribute to the discovery of molecules with antifungal properties
by microbial biotransformation procedures. Authors present some aspects of (1)
microbial biotransformation of herbal medicines and food; (2) possibility of major and
minor molecular amendments in existing molecules by biocatalysis; (3) methodological
improvements in processes involving whole cells and immobilized enzymes; (4) potential
of endophytic fungi to produce antimicrobials by bioconversions; and (5) in silico research
driving to the improvement of molecules. All these issues belong to a new conception of
transformation procedures, so-called “green chemistry,” which aims the highest possible
efficiency with reduced production of waste and the smallest environmental impact.
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INTRODUCTION
The search for new molecules has forced the pharmaceutical industry to modernize its synthetic
processes. Such modernization has occurred with the adoption of new techniques, such as
miniaturization, nanotechnology, microdosing, chemometrics, and high-throughput analysis (Koh
et al., 2003). Another aspect of modernization, so-called “Green Chemistry,” requires new synthetic
processes with the highest possible efficiency, resulting in reduced production of waste and the
smallest environmental impact (Tucker, 2006).
More than 20,000 molecules with antibiotic activity that are produced by microorganisms have
been described since the discovery of penicillin by Sir Alexander Fleming; however, only a small
fraction of them are clinically useful due to their toxicity. Since the 1980s, a decline in the discovery
of new molecules has been observed (Murphy, 2012).
The antifungal agents available on themarket act on different targets such as ergosterol synthesis,
chitin synthesis, glucan synthesis, nucleic acid synthesis, protein synthesis, microtubule synthesis,
or as inhibitors of squalene epoxidase or ergosterol disruptors (Kathiravan et al., 2012). However,
although there is substantial variability in the mechanisms of action and despite the technical
advances, the development of new antifungal drugs persists considering the co-evolution of
resistancemechanisms. Between 2006 and 2010, only one antifungal was approved for use, a natural
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echinocandin that was chemically changed by a semi-synthetic
route (Chen et al., 2011). In the last 30 years, among
the 28 new naturally occurring molecules, only three semi-
synthetic molecules that underwent chemical changes have been
authorized for clinical use (Newman and Cragg, 2012).
It is estimated that 25% of the world’s population presents
some episode of superficial mycosis and the mortality rate
associated with invasive fungal infections frequently exceeds
50%, even with the available antifungal medications. This
amount corresponds to approximately 1.5 million deaths
annually (Brown et al., 2012). Even under prophylactic use with
antifungals, some changes in epidemiological features have been
reported in more aggressive mucormicoses in patients using
voriconazole, as well as the rampant development of resistance
to azole by Aspergillus spp. (Perfect et al., 2014).
Echinocandins and allylamines are more modern drug classes
approved, but they date back to the 1970s and 1980s, respectively
(Odds, 2003). Echinocandins have been used as the treatment
of choice for systemic candidoses and are effective for strains
resistant to azoles (Zimbeck et al., 2010; Eschenauer et al., 2014);
however, a mutation in the FKS gene increases the resistance of
Candida spp. to echinocandins (Zimbeck et al., 2010; Beyda et al.,
2012). A multicenter study demonstrated that C. glabrata and C.
krusei have lost their susceptibility to caspofungin (24 and 52%,
respectively) and that other common Candida species are rapidly
losing their susceptibility to echinocandins (Zimbeck et al., 2010).
Even assuming great advances in synthetic chemistry,
biotransformation (or biocatalysis) remains the most cost-
effective path to discover new pharmaceuticals (Zaks and Dodds,
1997). Special attention should be given to the significant number
of drugs produced by microorganisms or by interactions with the
host from which they were isolated. Both cases contribute to the
idea that biotransformation processes shall expand significantly
in the future (Newman and Cragg, 2012). Nevertheless, there
are some questions regarding biotransformation that have to be
addressed: (1) How can structural changes occur in a way to
make the processes more time- and cost-efficient? (2) How can
the biological activity of products be enhanced by optimizing
the pharmacokinetic/pharmacodynamic (PK/PD) properties and
safety? (3) How may a supplier guarantee large-scale drug
production under good quality practices? (Bauer and Brönstrup,
2014).
With the appropriation of concepts from White
Biotechnology and Green Chemistry, this review aims to
assess the technological advances in the development of
microbial biotransformation products with antifungal activity.
MICROBIAL METABOLISM VS. MICROBIAL
BIOTRANSFORMATION
Natural products compose more than 2/3 of antibiotics used
in the medical/dental/veterinary practice (Schmitz et al., 2013).
Thus, it is not an erroneous statement to assume that active
substances from plants or those isolated from microorganisms
are the simplest way to search for new molecules. If they have
antifungal potential, some criteria must be observed (Barrett,
2002): (1) Do they present novel mechanisms of action or any
useful known mechanisms? (2) Is it possible to obtain clinical
proof with good biological activity? (3) Is it possible to change
the molecule to make it a tolerable drug? A good example of
a bioactive molecule obtained from plant extracts is eugenol,
which is extracted from Eugenia caryophillis (Indian clove). It is
a phenylpropanoid that presents considerable fungicidal activity
in vitro against C. albicans, and, unlike fluconazole, is also
effective against C. krusei and C. glabrata (Ahmad et al., 2010).
In addition to plants, microorganisms have provided some
bioactive molecules with remarkable antimicrobial activity,
especially in the last two decades.
For fungal infections, the glycopeptide occidiofungin A is
produced by Burkholderia contaminansMS14 and presents great
antifungal activity against pathogens of plants and animals (Lu
et al., 2009). Its mechanism of action has not been elucidated, but
it is assumed that it differs from the known classes and can bypass
fungal resistance problems (Tan et al., 2012). Benanomicin A and
benanomicin B are fermentatively produced by the cultivation
of Actinomadura spadix MH193-16F4 and are broad-spectrum
antimicrobials against various fungi including endemic and
opportunistic pathogens (Kumagai et al., 2008).
Although there remains a myriad of naturally occurring
secondary metabolites to be evaluated and discovered,
microbial biotransformation has emerged as an important
tool for obtaining novel structural analogs or to improve the
pharmacokinetic parameters of other substances (Parshikov
et al., 2000; Borges et al., 2008; Baydoun et al., 2014).
It is important to emphasize that metabolism and
biotransformation are distinct systems of molecular processing.
Microbial metabolism is composed of two major processes;
primary metabolism, which is responsible for cellular
function, and secondary metabolism, which uses pre-existing
metabolic pathways to produce substances from endogenous
intermediates to allow better adaptation of the organism to
the environment (Keller et al., 2005; Brakhage, 2013). Primary
metabolism consists of reactions associated with energy
generating, biomass production, and essential cell components.
Events such as glycolysis, oxidative phosphorylation, and
the Calvin-Benson cycle (in algae and photosynthesizing
bacteria) are examples of typical sets of reactions of primary
metabolism.
In contrast, secondary metabolism involves important events
for adaptation to environmental conditions. In general, it
generates low molar mass metabolites that are not essential for
growth but that offer some advantages and may sometimes have
medical/veterinary/agricultural/industrial importance. They
include antibiotics, pigments, anti-tumor agents, etc. They have
unusual structures and are normally synthesized during the late
phase of cell growth (Ruiz et al., 2010).
Regarding to antibiotics, it is estimated that actinomycetes
are responsible for 70–80% of all molecules produced by
secondary metabolism. Different species belonging to the genus
Streptomyces produces important antibiotics as chloramphenicol,
streptomycin, macrolides, and rifampicin, among others (Raja
and Prabakarana, 2011). A recent review regarding to this
theme presented new perspectives about the optimization in the
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production of actinomycetes-derived antibiotics (Antoraz et al.,
2015).
Biotransformation, sometimes inaccurately called “xenobiotic
metabolism,” is responsible for minor structural modifications
in exogenous substances by enzyme systems that lead to the
formation of molecules with relatively greater polarity (Asha
and Vidyavathi, 2009; Pervaiz et al., 2013). Phenomena such
as stereoselective hydroxylation, epoxidation, and oxidation are
common reactions attributed to biotransformation processes
and have been reported to occur in fungi (Farooq et al.,
2002; Choudhary et al., 2005, 2007, 2009, 2010; Al-Aboudi
et al., 2009). It is a mechanism that microorganisms developed
to adapt to environmental changes and it is useful in a
wide range of biotechnological processes (Crešnar and Petric,
2011).
One of the most remarkable features of biotransformation
reactions is the maintenance of the original carbon skeleton after
obtaining the products. Duringmetabolism, the carbon atoms are
transferred to other molecules with different chemical functions
(Figure 1).
Biotransformation reactions may involve various events such
as the formation of stable intermediates, which may be devoid
of toxic or pharmacologic activity. Sometimes, short-lived
reactants may also be generated. Further, biotransformation
reactions can result in chemically stable compounds with desired
pharmacological activity (Fura, 2006).
The use of microbial biotransformation is part of a new
movement named White Biotechnology, which is an emerging
field of modern biotechnology that serves industry. It employs
living cells (animals, plants, algae, filamentous fungi, yeast,
actinomycetes, and bacteria), as well as enzymes produced by
these cells during the generation of products of interest.
Wisely, Venisetty and Ciddi (2003) presented nine practical
advantages in the use of microbial systems as models for drug
metabolism:
(1) The low-cost and facility to maintain stock cultures of
microorganisms;
(2) Procedures with large number of strains are simple repetitive
processes;
(3) The concentrations of parental molecules used (generally
ranging from 0.2 to 0.5 g/L) are much higher than those
employed in other cell or tissue models;
FIGURE 1 | (A) Typical multi-step metabolic reactions, with deep alterations
on carbon skeleton (in this case, fatty acid oxidation). (B) Typical one-step
biotransformation reaction, with minor punctual alterations on carbon skeleton
(Adapted from: Hegazy et al., 2015).
(4) Novel products can be isolated with new or different
activities;
(5) There is a possibility to predict the most favored metabolic
reactions;
(6) The models can be scaled up easily for the preparation
of metabolites for pharmacological and toxicological
evaluation;
(7) These models can be utilized in synthetic reactions where
tedious steps are involved;
(8) In most cases, relatively mild incubation conditions are used;
(9) The models can be useful in cases where regio- and stereo-
specificity are involved, becoming molecular handling more
easily achieved by biotransformation than by synthetic
chemistry.
With regards to these last two statements, obtaining an
antimicrobial may become critically laborious if only chemical
procedures are employed, even for semi-synthetic compounds
(Wild, 1994; Claes et al., 2013). In this context, microbial
biotransformation becomes an attractive resource.
Living cells can be used in their original state (wild strains)
or improved to work as “cell factories” to produce enzymes or
consumer goods (Carballeira et al., 2009). Despite their potential,
the number and diversity of applications is still modest when
considering the wide availability of microorganisms, the large
number of reactions that they can achieve and the fact that
biotransformation reactions are considered economically and
ecologically competitive (Borges et al., 2009).
BIOTRANSFORMATION BY WHOLE CELLS
VS. IMMOBILIZED ENZYMES
It is insufficient to know the microbial biotransformation
pathways to establish whether they are economically useful;
rather, it is necessary to define reproducibility at a production
scale. This assumption demands some concern regarding
raw materials (the molecule to be biotransformed and the
microorganism/enzyme responsible for the reaction), equipment
(bioreactors), and the necessary technology to be employed in
the purification of the products (downstream processing). In
addition, it is imperative to take into account the lowest possible
production of pollutants and the highest possible enantiomeric
purity of the final product.
The criteria above are focuses of Green Chemistry that have
allowed the construction of chiral chemical building blocks that
lead to the development of enantiopure products obtained under
mild reaction conditions at physiological pH and temperature,
using water as reaction milieu and environmentally friendly
catalysts (enzymes or cells). The obtained products are usually
multifunctional molecules that exhibit highly chemo-regio-
stereoselective activity (Borges et al., 2009; Muñoz Solano et al.,
2012).
Immobilized enzymes are used for the conversion of
molecules in many industrial fields, although they are preferably
directed to simple catalytic processes. For the production of
antimicrobials, the applicability of individualized enzymes in
stricto sensu biotransformation processes is still incipient and
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little explored (Banerjee, 1993a,b; Mujawar, 1999; Takimoto et al.,
2004; Hormigo et al., 2010). Possibly, this may result from the
functional complexity required, which is readily attainable by
living organisms.
An important enzyme feature that has not been properly
explored is their promiscuity, which is the ability of enzymes
to catalyze different reactions with distinct catalytic mechanisms
to create new pathways (Wu et al., 2010). If we obtained
a new molecule with remarkable antifungal properties but
with inappropriate characteristics for ADMET (administration,
distribution, metabolism, excretion, and toxicity), it is possible to
“improve” its structure by enzyme promiscuity. For this, in silico
technologies favor technical development processes, predicting
PK/PD characteristics and increasing the use of immobilized
enzymes in the synthesis of pharmaceuticals.
Some complex processes of anti-proliferation production
via enzymatic biotransformation are already known. A good
example is the biosynthesis of griseofulvin from malonyl-CoA
using purified enzymes (Cacho et al., 2013). Several phases
including aldol condensation, cyclization, halogenation, and
oxidation are enzyme-mediated steps that can be reproduced
without the need of a living organism.
Penicillin G acylase (PGA) is one of the most relevant and
widely used biocatalysts for the industrial production of β-lactam
semisynthetic antibiotics (Srirangan et al., 2013). Such an enzyme
may be bulk produced as heterologous PGA in competent strains
such as Escherichia coliATCC R© 11105™ (Erarslan et al., 1990) or
Bacillus badius PGS10 (Rajendran et al., 2011).
Considering the processes using whole cells, it is assumed
that fungi are the organisms most commonly used to obtain
natural metabolic products and for biotransformation reactions
(Borges et al., 2009), even for the procurement of antifungal
drugs; however, microorganisms from other kingdoms may also
conduct dedicated biotransformation processes in order to obtain
antifungal molecules (Table 1).
The use of whole cells is advantageous once they present all
the needed enzymes and cofactors in adequate concentrations
and energy status. These favorable conditions may modulate the
activity of multienzymatic complexes and contribute to increase
conversion rates (Restaino et al., 2014).
The obtaining of biotransformation products may be
conducted using co-cultivation of two or more distinct entities.
It has been proposed by Wu et al. (2015), who reported
the increased obtaining of bioactive molecules during the co-
cultivation of Streptomyces coelicolor A3(2)M145 (actinomycete)
and Aspergillus niger N402 (fungus). According to the authors,
“growth in microbial communities or interactions between
different microorganisms is the next logical step in the search for
new molecules.”
Another interesting approach involves the possibility
of heterologous expression of biotransformation-related
cytochrome P450 enzymes from actinomycetes in bacteria to
obtain new antimycotic derivates (Kumagai et al., 2008). It
becomes useful for biotransformation procedures in large scale
producing plants where large bioreactors are employed.
It has been reported that pyrethrosin, a germacrane
sesquiterpene lactone commonly found in Chrysanthemum
cinerariaefoliumVisiani (Asteraceae), can be converted to several
new molecules by Cunninghamella elegans NRRL1392 and
Rhizopus nigricans NRRL1477 (Galal, 2001). Such filamentous
fungi are able to completely deplete pyrethrosin, transforming
it into five more polar metabolites that are very active
against Cryptococcus neoformans (IC50 = 25–35.0µg.mL−1) and
Candida albicans (IC50 = 10–30µg.mL−1).
The search for new antifungal molecules via microbial
biotransformation involves not only purified precursor
molecules, but may encompass complex substrates that can
be bioconverted into extracts rich in active substances.
Biotransformation products of cabbage-crude extracts
(Brassica oleracea var. capitata) processed by Pseudomonas
syringe pv. T1 showed promising inhibitory activity for
several Candida spp., with values close to those obtained for
amphotericin B (Bajpai et al., 2011). Pectobacterium atrosepticum
Pepto-A, a Gram-negative plant pathogen, can also be produced
from cabbage extracts to yield anti-Candida compounds (Bajpai
et al., 2012a).
Another Pectobacterium species, P. carotovorum subsp.
carotovorum 21, also presented the ability to biotransform
compounds found in cabbage (Bajpai et al., 2010a) and
in tomatoes (Solanun esculentum) to generate others with
remarkable activity against Candida spp. (Bajpai et al., 2012b,c).
Biotransformation has been successfully utilized as a tool
to generate pharmaceutical compounds from natural products.
Through this process, ethyl p-methoxycinnamate (EPMC) was
extracted from Kaempferia galanga (a Malaysian plant) and was
transformed using Aspergilus niger to ethyl p-hydroxycinnamate
(EPHC) (Omar et al., 2014). Looking at antimicrobial activities,
EPHC has a potential inhibitory effect against C. albicans that is
better than the effect by EPMC. This highlights the possibility of
increasing antifungal value to other known antifungal molecules.
Studies in this area shall be directed toward the diversification
of substrates combined with the numerous species of
biotransforming microorganisms. This can thus result in
the expansion of the antifungal library. In a recent review, a
number of molecules with antimicrobial activity derived from
monoterpenes have been described after biotransformation
processes by various microorganisms (Bhatti et al., 2014).
ENDOPHYTIC FUNGI PRODUCE
ANTIMICROBIALS BY
BIOTRANSFORMATION
Despite the substantial worldwide diversity, the discovery of
new families of bioactive molecules is surprisingly declining,
driving the need to bioprospect new sources (Joseph and Priya,
2011). Following such a thought, a group with promising
potential for new discoveries in the biotransformation area is
that of endophytic fungi. In recent years, endophytic fungi have
garnered great interest.
They are organisms that can grow either intra or
extracellularly in the tissues of higher plants in a clear mutualistic
relationship without causing any symptoms. Evidence shows
that they are a rich source of bioactive natural products. Active
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TABLE 1 | Antifungal molecules obtained by microbial biotransformation.
Antifungal chemical Biotransformer microorganism Parental chemical Antifungal activity Citation
bEPA
Pseudomonas aeruginosa NRRL-B-18602
Eicosapentaenoic acid Botrytis cinerea Bajpai et al., 2008
Colletotrichum capsici Bajpai and Kang, 2007
bDHA Docosahexaenoic acid Fusarium oxysporum Bajpai et al., 2009b
bEFA Hydroxifatty acids:
ricinoleic acid, linoleic acid,
eicosadienoic acid, etc
Fusarium solani
Phytophthora capsici
Rhizoctonia solani
Sclerotinia sclerotiorum
Bajpai et al., 2006
2,3-dihydrotrichostatin A Streptomyces venezuelae YJ028 Trichostatin A Saccharomyces cerevisiae Park et al., 2011
Ethyl p-hydroxycinnamate Aspergillus niger Ethyl p-methoxycinnamate Candida albicans Omar et al., 2014
9-keto-(-)-vasicine Aspergillus braziliensis ATCC®16404™ (-)-vasicine Candida albicans Gopkumar and
Mugeraya, 2010Penicillium notatum ATCC®36740™
Rhizopus arrizus ATCC®10260™
Trametes versicolor ATCC®20869™
5-p-menthene-1,2-diol Alternaria alternata NRRL20593 α-phellandrene Candida spp. I˙s¸can et al., 2012
Aspergillus alliaceus NRRL317
Aspergillus flavus
Botrytis cinerea AHU9424
Devosia riboflavina NRRL-B-784
Fusarium culmorum
Fusarium heterosporium DSM62719
Fusarium solani ATCC®1284™
Kluyveromyces lactis NRRL-Y-8279
Neurospora crassa N23 and N24
Phanerochaete chrysosporium ATCC®24725™
Saccharomyces cerevisae ATCC®9763™
Yarrowia lipolitica NRRL-Y-B423
Oxylipins Pseudomonas aeruginosa 42A2 Hydroxifatty acids:
ricinoleic acid, linoleic acid, oleic
acid, palmitic acid, etc.
Verticillium dhaliae Martin-Arjol et al., 2010
Macrophonia phaesolina
Arthroderma uncinatum
Trycophyton
mentagrophytes
Biotransformed galbonilides
I and II
Streptomyces halstedii ATCC®55964™ Galbonolides A and B Candida albicans Shafiee et al., 1999
Cryptococcus neoformans
metabolites of endophytics show positive actions as antibiotics,
immunosuppressives, anti-helminthics, antioxidants, and
anticancer drugs (Pimentel et al., 2011).
There is a noticeable increase in the rate of resistance
to antimicrobials, which is, at least in part, related to the
insufficient number of effective molecules and the small amount
of new antimicrobial agents in development, probably due to
unfavorable investment returns. In this context, the endophytic
fungi present themselves as an attractive alternative to modify the
current paradigm (Molina et al., 2012).
However, although a promising field, some problems cannot
be ignored in studies with endophytes. Special attention is
recommended in face of:
(1) The high nonspecific toxicity of some antimicrobials already
obtained;
(2) The fact that fungi tend to not produce toxic substances
against themselves, resulting in antimicrobial compounds
with moderate antifungal activity without potential as a
medicament or pesticide;
(3) The difficulty in large scale production of certain
antimicrobial compounds in artificial culture media;
(4) The biosynthesis and regulation of production of
antimicrobials from endophytes are partially or totally
unknown (Yu et al., 2010).
It is important to mention that many of the products related
to endophytics are derived from their secondary metabolism,
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and do not necessarily have a biotransformation background. In
some cases, it is not clear whether the final product is the result
of secondary metabolism or biotransformation. In spite of this
last finding, it is common sense amongst investigators devoted
to biotransformation that these fungi present vast potential
(Pimentel et al., 2011).
Table 2 presents some molecules with antifungal activity that
are produced exclusively by endophytic fungi via secondary
metabolism. As such, organisms that usually live in harsh
conditions in the presence of numerous natural compounds
are expected to be exceptional biotransforming entities (Shibuya
et al., 2003, 2005; Agusta et al., 2005; Fu et al., 2011; Maehara
et al., 2011; Huang et al., 2015; Khoyratty et al., 2015). Although
endophytic fungi are promising organisms for biotransformation
processes, their ability and potential to produce antimicrobial
molecules remain unexplored.
CANDIDATE MOLECULES FOR
BIOTRANSFORMATION
One point of concern when evaluating the feasibility of
producing antifungals via microbial biotransformation is the
choice of parental molecules to be modified. Such chemicals
must not be toxic or inhibitory to the biotransforming organism.
However, this can be circumvented if the concentrations during
fermentation processes remain inferior to those considered as
inhibitory.
Accumulated data has revealed that some classes of molecules
seem to be more ready to undergo biotransformation and
generate antifungals.
Some unsaturated fatty acids have shown interesting results.
Bajpai et al. (2009a, 2010b) have conducted extensive reviews
regarding this matter and reported that Pseudomonas aeruginosa
NRRL-B-18602 PR3 produced mono-, di-, and tri-hydroxy fatty
acid derivatives from unsaturated fatty acids with recognized
antifungal properties. This bacterium can convert oleic acid
to 7,10-dihydroxy-8(E)-octadecenoic acid, an anticandidal
compound (Hou and Forman, 2000).
Other unsaturated fatty acids can also undergo oxidation
in the presence of bacteria (Pseudomonas sp. 42A2 or Bacillus
megaterium ALA2 NRRL-B-21660) or plants (Colocassia
antiquorum) to produce mono-, di-, and tri-hydroxy fatty
acids with antifungal potential such as 15,18-dihydroxy-14,17-
epoxy-5(Z),8(Z),11(Z)-eicosatrienoic acid, 17,20-dihydroxy-16,
19-epoxy-4(Z),7(Z),10(Z),13(Z)-docosatetraenoic, 9,12,13-
trihydroxy-(E)-octadecenoic acid, 12,13,16-trihydroxy-9(Z)-
octadecenoic acid, and 12,13,17-trihydroxy-9(Z)-octadecenoic
acid (Masui et al., 1989; De Andrés et al., 1994; Hou, 1996; Hou
et al., 1997; Hosokawa et al., 2003a,b).
Based on the mechanism proposed for (Z)-9-heptadecenoic
acid (Avis and Bélanger, 2001), the most probable antifungal
mechanism of action must involve the disruption or
disintegration of the plasma membrane caused by a hydrostatic
turgor pressure within the cell resulting in the release of
intracellular electrolytes and proteins (Carballeira, 2008).
Another class of molecules with a promising outlook are
sterols. This class of substances has been evaluated in relation
to their ability to be biotransformed for many years (Mahato
and Mukherjee, 1984; Mahato and Garai, 1997; Holland, 1999;
Malaviya and Gomes, 2008; Bhatti and Khera, 2012; Donova
and Egorova, 2012). Surprisingly, there are few investigations
on the production of antifungals, despite the fact that many
compounds such as 24-amino-lanosterol, 24-amino-cholesterol,
and 24-amino-cholesterol-N-sulfate possess potent antifungal
activities against Candida spp., C. neoformans, and Trichophyton
mentagrophytes (Chung et al., 1998).
Preliminary studies have shown that steroids and steroidal
lactones biotransformed by Cunninghamella spp. produce
metabolites with leishmanicidal activity (Choudhary et al., 2006;
Baydoun et al., 2014). It is reasonable that such metabolites
act on the synthetic pathway of ergosterol in Leishmania spp.
We speculate that these putative mechanisms of action may be
extrapolated to fungi, which should encourage investigators to
drive their efforts toward this problem.
Alkaloids may also be converted into antifungal compounds.
As part of an extensive program which aimed the discovery
and development of antimicrobials from higher plants, Orabi
and colleagues conducted a series of experiments in order to
obtain antifungals from sampangine, an alkaloid found in the
West African tree Cleistophathis patens (Annonaceae) (Orabi
et al., 1999). Their results showed that Beauveria bassiana
ATCC R©7159™, Doratomyces microsporus ATCC R©16225™,
and Filobasidiella neoformans ATCC R©10226™ produced the
4′-O-methyl-β-glucopyranose conjugate, while Absidia glauca
ATCC R©22752™, Cunninghamella elegans ATCC R©9245™,
Cunninghamella sp. NRRL5695, and Rhizopus arrhizus
ATCC R©11145™ produced the β-glucopyranose conjugate.
Both metabolites presented significant in vitro activity against C.
neoformans, but were inactive against C. albicans (Orabi et al.,
1999).
The same group published interesting results about the
biotransformation of the synthetic antifungal alkaloid
benzosampangine (Orabi et al., 2000). They showed that
Absidia glauca ATCC R©22752™, Cunninghamella blakesleeana
ATCC R©8688a™, Cunninghamella sp. NRRL5695, Fusarium
solani f. sp. cucurbitae CSIH#C-5, and Rhizopogon species
ATCC R©36060™ each produced a β-glucopyranose conjugate
of benzosampangine. Such a substance possesses good in vitro
antifungal activity against C. albicans, Aspergillus fumigatus
(MIC = 0.39µg.mL−1; amphotericin B: 0.78µg.mL−1 and
0.39µg.mL−1, respectively), and C. neoformans (MIC =
1.56µg.mL−1; amphotercin B, 0.39µg.mL−1). The authors
emphasized that microbial biotransformation is reliable and
produces significant quantities of metabolites. In addition,
they showed that alkaloids could be converted into conjugate
metabolites with increased antifungal activity.
IN SILICO PREDICTIVE IMPROVEMENT OF
BIOPROCESSABLE MOLECULES
In silico is the term used to define experimentation carried out in
computers. In turn, in silico pharmacology is a large growing area
that helps to develop molecular arrangements using dedicated
software to capture, analyze and integrate biological and medical
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TABLE 2 | Antifungal molecules obtained from secondary metabolism of endophytic fungi.
Antifungal chemical Endophytic fungi Origin Antifungal activity Citation
Camptothecin Colletotrichum sp. Artemisia annua Various human and plant
pathogensPericonicin A and B
Phomol Guo et al., 2008
Pyrrocidines A and B Acremonium zeae NRRL13540 Zea mays Aspergillus flavus
Fusarium verticillioides
Sordaricin Xylaria sp. PSU-D14 Garcinia dulcis Candida albicans Pongcharoen et al., 2008
Lactone multiplolides A and B Xylaria multiplex BCC 1111 Unidentified Thai tree Candida albicans Boonphong et al., 2001
7-amino-4-methylcoumarin Xylaria sp. YX-28 Gynkgo biloba Aspergillus niger Liu et al., 2008
Candida albicans
Penicillium. expansum
Griseofulvin Xylaria sp. F0010 Abies holophylla Blumeria graminis f. sp.
hordei
Park et al., 2005
Corticium sasaki
Magnaporthe grisea
Puccinia recondite
Chaetomugilin A and D Chaetomium globosum Ginkgo biloba Mucor miehei Qin et al., 2009
Cytosporone B and C Phomopsis sp. ZSU-H76 Excoecaria agallocha Candida albicans
Fusarium oxysporum
Huang et al., 2008
(-)-Mycorrhizin A
(+)-Cryptosporiopsin
Pezicula spp. Various German trees Euratium repens Schulz et al., 1995
Mycatypha micraspara
Ustilaga vialacea
Pestalachlorides A, B, and C Pestalotiopsis adusta (L416) Unidentified Chinese tree Fusarium culmorum Li et al., 2008
Gibberella zeae
Verticillium albo-atrum
Emodin
Hypericin
Thielavia subthermophila Hypericum perforatum Aspergillus niger Kusari et al., 2008, 2009;
Kusari and Spiteller, 2011Candida albicans
Brefeldin A Cladosporium sp. Quercus variabilis Aspergillus niger Wang et al., 2007
Candida albicans
Epidermophyton floccosum
Microsporum canis
Trichophyton rubrum
Cytochalasin D
2-hexyl-3-methyl-butanodioic acid
Xylaria sp Palicourea marcgravii Cladosporium
cladosporioides
Cladosporium
sphaerospermum
Cafêu et al., 2005
Ethyl
2,4-dihydroxy-5,6-dimethylbenzoate
Phomopsilactone
Phomopsis cassia Cassia spectabilis Silva et al., 2005
Asperfumoid Aspergillus fumigatus CY018 Cynodon dactylon Candida albicans Liu et al., 2004
Fumigaclavine C
Fumitremorgin C
Helvolic acid
Physcion
(Continued)
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TABLE 2 | Continued
Antifungal chemical Endophytic fungi Origin Antifungal activity Citation
2,6-diOH-2-methyl-7-(prop-1E-enyl)-
1-benzofuran-3(2H)-one
Ergosterol peroxide
Verticillium sp. Rehmannia glutinosa Fusarium sp. You et al., 2009
Rhizoctonia sp.
Septoria sp.
data (Ekins et al., 2007). The use of in silico techniques allows
the prediction of the pharmacokinetic aspects of absorption,
distribution, biotransformation and excretion of new substances.
It can be assumed that in silico projections of newmolecules allow
the prioritization of chemicals to be tested, identifying hazard and
risk assessment (Kulkarni et al., 2005). The computer-assisted
simulations based on pharmacological and biological data reduce
time and costs during the screening of new substances once
they cease to categorize undesirable molecules with improper
characteristics during the early stages of discovery.
In addition, it is possible to evaluate the coupling of molecules
to their possible targets. Using databases of 3D molecular
structures, it is possible to anticipate connections between new
molecules and possible binding sites. Numerous substances have
been evaluated by this method, and it was possible to propose
important features of some of them as the mechanism of
action of antifungal piranocoumarins and antibacterial xanthone
derivatives (Do et al., 2015).
CaCYP51 is a sterol 14-α demethylase that binds the
CYP51 substrates lanosterol and eburicol in C. albicans. In
silico techniques based on the molecular structure of CaCYP51
have allowed the development of new azoles by replacing
the side chains provided in the simulation. The new azoles
showed excellent antifungal activity in vitro with broad spectrum
(Che et al., 2009). The development of new molecules in
silico largely depends on the molecular recognition of possible
couplings between the drug and microorganisms. Therefore,
once elucidated, the mechanism of action of an antifungal
obtained by biotransformation will allow the simulation of
molecules with improved pharmacokinetic characteristics and
may accelerate the development of potential drugs (Rask-
Andersen et al., 2011).
PERSPECTIVES
The prospection of new molecules, principally from endophytic
fungi, is a vast field of study with huge potential for growth.
However, consistent efforts are necessary to achieve results.
Professionals from the fields of biotechnology, pharmacology,
computer sciences, engineering and some other related areas
have to work closely together to explore possible binding sites
for new and existing molecules. The use of in silico analyses
anticipate investigations in a timesaving manner and reduce the
demands for inputs and even animals used in the initial tests.
These features drive future research toward the development
of new and feasible technologies within the Green Chemistry
guidelines connected to the principle of the 3Rs (replacement,
reducing, refinement) for the use of experimental animals
(Russell and Burch, 1959).
A reasonable research design for the prospecting of new
antifungal drugs under the above stated conditions involves the
following:
(1) The in silico analysis of existing molecules for possible new
couplings to different targets;
(2) The in silico identification of necessary changes in the
precursor molecule for effective coupling on targets;
(3) In the absence of new discoveries, the biotransformation of
various candidate substrates for obtaining new molecules;
(4) The recognition of which organisms or isolated enzymes
may modify structural precursor molecules to yield
enantiomerically pure antifungal molecules based on the
theory of enzyme promiscuity;
(5) The in silico evaluation of toxicity for newly developed
antifungal molecules;
(6) The process of scaling up with environmentally friendly
inputs to test the economic viability.
Once the goals outlined above are achieved, the investigator is
ready to conduct clinical trials to confirm the PK/PD properties,
security, and all other steps necessary for commercialization of
the drug.
It is important to notice that with the advent of in silico
technologies, laboratory tests tend to reduce theirmargin of error,
and therefore, save both environmental and financial resources.
However, they primarily accelerate new discoveries to minimize
the impact of developed resistance to existing drugs.
Therefore, it is necessary to sequence and deposit the
genomes of microorganisms with biotransformation capacity in
databases. In addition, further study on the molecular structure
of possible targets in pathogenic fungi is mandatory. This will
provide subsidies to find coupling regions for the developed
molecules.
Currently, we have high cost and low return as factors related
to the decline in the development of new antimicrobial drugs.
There is no other way to achieve such a market if the costs
of research are not reduced and production is enabled in a
sustainable way.
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